AVROBIO, Inc. approved transaction bonuses for its President, Interim CEO, CFO, and Treasurer, and Chief Technology Officer in connection with the sale of its cystinosis gene therapy program. The company also held its 2023 Annual Meeting of Stockholders, where director nominees were elected and the appointment of Ernst & Young LLP as the independent registered public accounting firm was ratified.